[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Liang, M.-Q., Yu, F.-Q. and Chen, C. (2020) C-Myc Regulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma. American Journal of Translational Research, 12, 379-388.
|
[3]
|
Lu, D., Liu, X., Feng, S., et al. (2019) The Current Situation of Esophageal Cancer Staging and Perioper-ative Strategies Determination in Central and Southern China: A Cross Sectional Survey. Frontiers in Oncology, 9, Arti-cle No. 1098. https://doi.org/10.3389/fonc.2019.01098
|
[4]
|
Liu, W., Huo, G. and Chen, P. (2023) Efficacy of PD-1/PD-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis. Immuno-therapy, 15, 751-771. https://doi.org/10.2217/imt-2022-0305
|
[5]
|
Dedecker, H., Teuwen, L.-A., Vandamme, T., et al. (2023) The Role of Immunotherapy in Esophageal and Gastric Cancer. Clinical Colorectal Cancer, 22, 175-182. https://doi.org/10.1016/j.clcc.2023.03.001
|
[6]
|
Yi, M., Niu, M., Xu, L., et al. (2021) Regulation of PD-L1 Expres-sion in the Tumor Microenvironment. Journal of Hematology & Oncology, 14, Article No. 10. https://doi.org/10.1186/s13045-020-01027-5
|
[7]
|
Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., et al. (2017) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 377, 1345-1356.
https://doi.org/10.1056/NEJMoa1709684
|
[8]
|
Kudo, T., Hamamoto, Y., Kato, K., et al. (2017) Nivolumab Treat-ment for Oesophageal Squamous-Cell Carcinoma: An Open-Label, Multicentre, Phase 2 Trial. The Lancet Oncology, 18, 631-639.
https://doi.org/10.1016/S1470-2045(17)30181-X
|
[9]
|
Janjigian, Y.Y., Bendell, J., Calvo, E., et al. (2018) Check-Mate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab plus Ipilimumab in Patients with Metastatic Esoph-agogastric Cancer. Journal of Clinical Oncology, 36, 2836-2844. https://doi.org/10.1200/JCO.2017.76.6212
|
[10]
|
Kojima, T., Muro, K., Francois, E., et al. (2019) Pembrolizumab versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer: Phase III KEYNOTE-181 Study. Journal of Clinical Oncology, 37, 2.
https://doi.org/10.1200/JCO.2019.37.4_suppl.2
|
[11]
|
Garon, E.B., Hellmann, M.D., Rizvi, N.A., et al. (2019) Five-Year Overall Survival for Patients with Advanced Non‒Small-Cell Lung Cancer Treated with Pembrolizumab: Re-sults from the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 37, 2518-2527. https://doi.org/10.1200/JCO.19.00934
|
[12]
|
Hamid, O., Robert, C., Daud, A., et al. (2019) Five-Year Survival Outcomes for Patients with Advanced Melanoma Treated with Pembrolizumab in KEYNOTE-001. Annals of Oncology, 30, 582-588.
https://doi.org/10.1093/annonc/mdz011
|
[13]
|
Ishida, Y., Agata, Y., Shibahara, K., et al. (1992) Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, upon Programmed Cell Death. The EMBO Jour-nal, 11, 3887-3895.
https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
|
[14]
|
Carreno, B.M. and Collins, M. (2002) The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses. Annual Review of Immunology, 20, 29-53.
https://doi.org/10.1146/annurev.immunol.20.091101.091806
|
[15]
|
Ratajczak, K., Grel, H., Olejnik, P., et al. (2023) Current Progress, Strategy, and Prospects of PD-1/PDL-1 Immune Checkpoint Biosensing Platforms for Cancer Diag-nostics, Therapy Monitoring, and Drug Screening. Biosensors and Bioelectronics, 240, Article ID: 115644. https://doi.org/10.1016/j.bios.2023.115644
|
[16]
|
Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Current Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
|
[17]
|
Yang, Q., Shi, G., Chen, X., et al. (2020) Nanomicelle Protects the Immune Activation Effects of Paclitaxel and Sensitizes Tumors to Anti-PD-1 Immuno-therapy. Theranostics, 10, 8382-8399. https://doi.org/10.7150/thno.45391
|
[18]
|
Sudo, S., Kajiya, H., Okano, S., et al. (2020) Cisplatin-Induced Programmed Cell Death Ligand-2 Expression Is Associated with Metastasis Ability in Oral Squamous Cell Carcinoma. Cancer Science, 111, 1113-1123.
https://doi.org/10.1111/cas.14336
|
[19]
|
Wu, X., Ke, X., Ni, Y., et al. (2020) Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. Journal of Immunology Research, 2020, Article ID: 8884683.
https://doi.org/10.1155/2020/8884683
|
[20]
|
Lantuejoul, S., Damotte, D., Hofman, V., et al. (2019) Programmed Death Ligand 1 Immunohistochemistry in Non-Small Cell Lung Carcinoma. Journal of Thoracic Disease, 11, S89-S101.
https://doi.org/10.21037/jtd.2018.12.103
|
[21]
|
Cui, Y., Shi, J., Cui, Y., et al. (2023) The Relationship between Au-tophagy and PD-L1 and Their Role in Antitumor Therapy. Frontiers in Immunology, 14, Article ID: 1093558. https://doi.org/10.3389/fimmu.2023.1093558
|
[22]
|
Lv, G., Sun, X., Qiu, L., et al. (2020) PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody. Journal of Nuclear Medicine, 61, 117-122. https://doi.org/10.2967/jnumed.119.226712
|
[23]
|
Shi, F., Shi, M., Zeng, Z., et al. (2011) PD-1 and PD-L1 Upregulation Promotes CD8+ T-Cell Apoptosis and Postoperative Recurrence in Hepatocellular Carcinoma Patients. In-ternational Journal of Cancer, 128, 887-896.
https://doi.org/10.1002/ijc.25397
|
[24]
|
Patsoukis, N., Sari, D. and Boussiotis, V.A. (2012) PD-1 Inhibits T Cell Proliferation by Upregulating p27 and p15 and Suppressing Cdc25A. Cell Cycle, 11, 4305-4309. https://doi.org/10.1002/ijc.25397
|
[25]
|
Mansfield, A.S., Aubry, M.C., Moser, J.C., et al. (2016) Temporal and Spa-tial Discordance of Programmed Cell Death-Ligand 1 Expression and Lymphocyte Tumor Infiltration between Paired Primary Lesions and Brain Metastases in Lung Cancer. Annals of Oncology, 27, 1953-1958. https://doi.org/10.1093/annonc/mdw289
|
[26]
|
Velcheti, V., Rimm, D.L. and Schalper, K.A. (2013) Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1). Journal of Thoracic Oncology, 8, 803-805. https://doi.org/10.1097/JTO.0b013e318292be18
|
[27]
|
Rollins, M.R. and Gibbons Johnson, R.M. (2017) CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells. Journal of Im-munology Research, 2017, e7659462.
https://doi.org/10.1155/2017/7659462
|
[28]
|
Sanmamed, M.F. and Chen, L. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 175, 313-326. https://doi.org/10.1155/2017/7659462
|
[29]
|
Cheng, C., Zhuge, L., Xiao, X., et al. (2022) Overcoming Resistance to PD-1/PD-L1 Inhibitors in Esophageal Cancer. Frontiers in Oncology, 12, Article No. 955163. https://doi.org/10.3389/fonc.2022.955163
|
[30]
|
Hu, C., Meiners, S., Lukas, C., et al. (2020) Role of Exosomal mi-croRNAs in Lung Cancer Biology and Clinical Applications. Cell Proliferation, 53, e12828. https://doi.org/10.1111/cpr.12828
|
[31]
|
Chen, K., Cheng, G., Zhang, F., et al. (2016) Prognostic Significance of Programmed Death-1 and Programmed Death-Ligand 1 Expression in Patients with Esophageal Squamous Cell Carci-noma. Oncotarget, 7, 30772-30780.
https://doi.org/10.18632/oncotarget.8956
|
[32]
|
Liu, Z., Sun, L., Cai, L., et al. (2022) Clinicopathological and Prog-nostic Values of PD-L1 Expression in Oesophageal Squamous Cell Carcinoma: A Meta-Analysis of 31 Studies with 5368 Patients. Postgraduate Medical Journal, 98, 948-957. https://doi.org/10.18632/oncotarget.8956
|
[33]
|
Jesinghaus, M., Steiger, K., Slotta-Huspenina, J., et al. (2017) In-creased Intraepithelial CD3+ T-Lymphocytes and High PD-L1 Expression on Tumor Cells Are Associated with a Fa-vorable Prognosis in Esophageal Squamous Cell Carcinoma and Allow Prognostic Immunogenic Subgrouping. Onco-target, 8, 46756-46768.
https://doi.org/10.18632/oncotarget.18606
|
[34]
|
Zhang, W., Pang, Q., Zhang, X., et al. (2017) Programmed Death-Ligand 1 Is Prognostic Factor in Esophageal Squamous Cell Carcinoma and Is Associated with Epidermal Growth Factor Receptor. Cancer Science, 108, 590-597.
https://doi.org/10.1111/cas.13197
|
[35]
|
Jiang, Y., Chen, M., Nie, H., et al. (2019) PD-1 and PD-L1 in Cancer Im-munotherapy: Clinical Implications and Future Considerations. Human Vaccines & Immunotherapeutics, 15, 1111-1122.
https://doi.org/10.1080/21645515.2019.1571892
|
[36]
|
Doki, Y., Ajani, J.A., Kato, K., et al. (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 386, 449-462.
https://doi.org/10.1080/21645515.2019.1571892
|
[37]
|
Kato, K., Cho, B.C., Takahashi, M., et al. (2019) Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Pre-vious Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 1506-1517.
https://doi.org/10.1016/S1470-2045(19)30626-6
|
[38]
|
Shah, M.A., Kojima, T., Hochhauser, D., et al. (2019) Effi-cacy and Safety of Pembrolizumab for Heavily Pretreated Patients with Advanced, Metastatic Adenocarcinoma or Squa-mous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncology, 5, 546-550. https://doi.org/10.1001/jamaoncol.2018.5441
|
[39]
|
Kojima, T., Shah, M.A., Muro, K., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38, 4138-4148. https://doi.org/10.1200/JCO.20.01888
|
[40]
|
Sun, J.-M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. The Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|